Mandate

Vinge advises IRLAB Therapeutics in connection with a directed share issue

May 24, 2018

The board of directors of IRLAB Therapeutics has, on the basis of an authorisation granted from the annual general meeting, resolved on a directed new issue of shares, whereby IRLAB Therapeutics will raise proceeds of SEK 138,6 million, before issue costs.

The share issue is directed to a number of selected institutional investors in Sweden and the US. 
 
IRLAB Therapeutics is a research and development company, listed on Nasdaq First North Premier, focused on development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson’s disease and dementia.
 
Vinge’s team has consisted of Dain Hård Nevonen, Sofie Bjärtun and Hampus Olsson
 
 

Related

Vinge advises Right Side Group, a portfolio company of Alder, in connection with the acquisition of Brandkonsultbyrån i Sverige

Brandkonsultbyrån in Sweden is a technical consultant specialising in structural fire protection, evacuation safety and risk management. The acquisition strengthens the group’s position as a leading player in fire, risk and safety in the Nordic region.
April 17, 2026

Vinge advises Vidia Climate Fund I in connection with the acquisition and acquisition financing of ABEKA El & Kraftanläggningar AB

Vinge has acted as legal adviser to Vidia Climate Fund I in connection with the acquisition and acquisition financing of ABEKA El & Kraftanläggningar AB from Bravida and certain minority shareholders. ABEKA El & Kraftanläggningar AB is a highly specialized electrical grid services and project management provider.
April 17, 2026

Vinge advises Lagercrantz Group on the acquisition of Nivex Topsafe

Lagercrantz Group AB (publ) has acquired the shares in Nivex Topsafe AB, a leading player in the Swedish market for secure storage solutions such as security and fire-rated safes as well as secure rooms, with operations in Sweden and Poland.
April 17, 2026